Targeting the cell cycle in esophageal adenocarcinoma:An adjunct to anticancer treatment

查看全文 作　　者：Martyn [1]Dibb;Yeng S [2]Ang

机构地区：[1]Department of Gastroenterology,Royal Albert Edward Infirmary;[2]School of Translational Medicine,Faculty of Medical and Human Sciences,The University of Manchester

出　　处：《World Journal of Gastroenterology》索引2011年第17卷第16期,共7页

基　　金：Supported by UK National Institute of Health Research/Cancer Research Network and Research and Development Department of Wrightington Wigan and Leigh NHS Foundation Trust (to Ang YS);Wrightington Wigan and Leigh NHS Foundation Trust Cancer Therapy Fund (to Dibb M) 摘　　要：Esophageal adenocarcinoma is a major cause of cancer death in men in the developed world.Continuing poor outcomes with conventional therapies that predominantly target apoptosis pathways have lead to increasing interest in treatments that target the cell cycle.A large international effort has led to the development of a large number of inhibitors,which target cell cycle kinases,including cyclin-dependent kinases,Aurora kinases and polo-like kinase.Initial phase Ⅰ/Ⅱ trials in solid tumors have often demonstrated only modest clinical benefits of monotherapy.This may relate in part to a failure to identify the patient populations that will gain the most clinical benefit.Newer compounds lacking the side effect profile of first-generation compounds may show utility as adjunctive treatments targeted to an individual's predicted response to treatment. 关键词：细胞周期蛋白激酶辅助治疗细胞周期蛋白依赖性激酶腺癌食道抗癌定位 AURORA

相关文献

参考文献（78）
引证文献（7）
耦合文献（0）

参考文献(78)

引证文献(7)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Targeting the cell cycle in esophageal adenocarcinoma:An adjunct to anticancer treatment

参考文献(78)

引证文献(7)

用户提示